Business

Neurim Pharmaceuticals markets its new drugs through strategic alliances with reputable marketing and distribution partners on whose marketing expertise we rely.

Neurim has so far established marketing and sales agreements with Teva, Takeda, Aspen Pharmacare, DKSH, Flynn, Medice, Italfarmaco, Biocodex, Kuhnil Pharm, Fidia, Juste and Biopas.
We are actively seeking additional strategic alliances.

Please feel free to contact us:

Dr. Hansjoerg Jakubetz
Director Corporate Business Development
Email: business@neurim.com

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners